Under these conditions, ZEB1/p53-dcKO CAFs retain the ability to express FGF2 (i.e., ZEB1 is no longer required to repress p53), thereby retaining the ability to repress p53 protein levels in PyMT-cancer cells in vivo and in vitro. This evidence concerns the gene FGF2 and cancer.